Advertisement
Published in:
Open Access 01-11-2021 | Original Article
Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study
Authors: J. J. van Kleef, W. P. M. Dijksterhuis, H. G. van den Boorn, M. Prins, R. H. A. Verhoeven, S. S. Gisbertz, M. Slingerland, N. Haj Mohammad, G.-J. Creemers, K. J. Neelis, J. Heisterkamp, C. Rosman, J. P. Ruurda, E. A. Kouwenhoven, L. V. van de Poll-Franse, M. G. H. van Oijen, M. A. G. Sprangers, H. W. M. van Laarhoven, On behalf of the Dutch Upper GI Cancer Group (DUCG)
Published in: Gastric Cancer | Issue 6/2021
Login to get accessAbstract
Background
Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall survival (OS) in oesophagogastric cancer. However, real-world data are lacking. Moreover, differences in disease stages and tumour-specific symptoms are usually not taken into consideration. The aim of this population-based study was to assess the prognostic value of HRQoL, including tumour-specific scales, on OS in patients with potentially curable and advanced oesophagogastric cancer.
Methods
Data were derived from the Netherlands Cancer Registry and the patient reported outcome registry (POCOP). Patients included in POCOP between 2016 and 2018 were stratified for potentially curable (cT1-4aNallM0) or advanced (cT4b or cM1) disease. HRQoL was measured with the EORTC QLQ-C30 and the tumour-specific OG25 module. Cox proportional hazards models assessed the impact of HRQoL, sociodemographic and clinical factors (including treatment) on OS.
Results
In total, 924 patients were included. Median OS was 38.9 months in potentially curable patients (n = 795) and 10.6 months in patients with advanced disease (n = 129). Global Health Status was independently associated with OS in potentially curable patients (HR 0.89, 99%CI 0.82–0.97), together with several other HRQoL items: appetite loss, dysphagia, eating restrictions, odynophagia, and body image. In advanced disease, the Summary Score was the strongest independent prognostic factor (HR 0.75, 99%CI 0.59–0.94), followed by fatigue, pain, insomnia and role functioning.
Conclusion
In a real-world setting, HRQoL was prognostic for OS in patients with potentially curable and advanced oesophagogastric cancer. Several HRQoL domains, including the Summary Score and several OG25 items, could be used to develop or update prognostic models.
